Bilateral Candida Endophthalmitis – Successful Treatment by Single Amphotericin B Injection in Combination with Systemic Antimycotic Treatment

Background

Ocular candidiasis is a severe intraocular fungal infection caused by various species of Candida, most commonly, by the yeast species Candida albicans [1] [2] [3] [4]. The literature distinguishes Candida chorioretinitis from Candida endophthalmitis, the latter term being reserved for cases with significant vitritis. Since Candida is normally distributed throughout the gastrointestinal tract, invasive procedures increase the risk of candidemia, which is an essential component in the pathogenesis of endogenous Candida endophthalmitis and chorioretinitis [1]. In patients with candidemia, the organisms reach the choroid and retina through hematogenous spread and then proliferate, causing subretinal, choroidal, and intraretinal abscess formation and subsequent vitreous involvement [1]. The rates of developing ocular candidiasis in candidemia are reported to be between 2 and 9% [1].

This report aims to contribute to the understanding and management of Candida endophthalmitis.

We present an 84-year-old man with mycological confirmed candidemia successfully treated by a single amphotericin B injection and systemic fluconazole over a follow-up period of 3 months and discuss the treatment in relation to other approaches.

Publikationsverlauf

Eingereicht: 27. Oktober 2024

Angenommen: 17. Februar 2025

Artikel online veröffentlicht:
16. April 2025

• References

• 1 Bae JH, Lee SC. Intravitreal liposomal amphotericin B for treatment of endogenous candida endophthalmitis. Jpn J Ophthalmol 2015; 59: 346-352
• 2 Daiki D, Imai H, Nakamura M. Multiple Intravitreal Liposomal Amphotericin B for a Case of Candida glabrata Endophthalmitis. Case Rep Ophthalmol 2021; 12: 485-491
• 3 William A, Spitzer MS, Deuter C. et al. Outcomes of Primary Transconjunctival 23-Gauge Vitrectomy in the Diagnosis and Treatment of Presumed Endogenous Fungal Endophthalmitis. Ocul Immunol Inflamm 2017; 25: 239-245
• 4 Regan KA, Radhakrishnan NS, Hammer JD. et al. Endogenous Endophthalmitis: yield of the diagnostic evaluation. BMC Ophthalmol 2020; 20: 138
• 5 Thangamathesvaran L, Canner JK, Scott AW. et al. National emergency department trends for endogenous endophthalmitis: an increasing public health challenge. Eye (Lond) 2023; 37: 1123-1129
• 6 Essman TF, Flynn jr. HW, Smiddy WE. et al. Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers 1997; 28: 185-194
• 7 Durand ML. Endophthalmitis. Clin Microbiol Infect 2013; 19: 227-234
• 8 Burton E, Reddy V, Venkat AG. Endogenous Fungal Endophthalmitis: A Single-Center Retrospective Study and Review of the Literature. Am J Ophthalmol 2024; 262: 97-106
• 9 Khan FA, Slain D, Khakoo RA. Candida endophthalmitis: focus on current and future antifungal treatment options. Pharmacotherapy 2007; 27: 1711-1721
• 10 Gabel-Pfisterer A, Kischio S, Keen M. et al. Operative Therapie und Keimnachweis bei endogener Endophthalmitis: Datenauswertung aus 5 Augenkliniken. Ophthalmologie 2024; 121: 282-290
• 11 Deivarajan HR, R PS. Elamurugan V. et al. Clinical Evaluation of a Novel CRISPR-Cas12a-Based RID-MyC Assay for the Diagnosis of Fungal Endophthalmitis. Ophthalmol Retina 2024;